Medicago’s facility is designed to research and produce plant-based commercial-grade vaccines. It includes a 27,000 sf fully automated greenhouse and headhouse, as well as extensive laboratory, production and office space. This revolutionary hybrid facility represents the intersection of some of the most advanced science in biotechnology and pharmaceutical vaccine research and production. The greenhouse has a plant capacity of 90,000 plants and incorporates customized robotics and infiltration equipment. A state-of-the-art extraction and purification unit was also installed. Construction included Class A (1,000), B (10,000) and C (100,000) modular clean rooms. The project received substantial federal funding from the Defense Advanced Research Projects Agency (DARPA) to demonstrate the scalable manufacturing of its plant-expressed Virus-Like Particle (VLP) vaccines.